Search Results - Mohamed‐Eslam F. Mohamed

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials by Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K. Anderson, Mohamed‐Eslam F. Mohamed

Connect to this object online.

Upadacitinib: Mechanism of action, clinical, and translational science by Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung

Connect to this object online.

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis by Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed

Connect to this object online.

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study by Hari V. Kalluri, Ryota Kikuchi, Sheryl Coppola, Jeffrey Schmidt, Mohamed‐Eslam F. Mohamed, Daniel A.J. Bow, Ahmed H. Salem

Connect to this object online.

Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis by Mohamed‐Eslam F. Mohamed, Yuli Qian, Ronilda D'Cunha, Teresa Sligh, Laura K. Ferris, Ann Eldred, Gweneth F. Levy, Shuai Hao, Shashikanth Gannu, David G. Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati

Connect to this object online.